We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook
Read MoreHide Full Article
Key Takeaways
ABT Medical Devices sales rose 8.5% in Q1, led by strong cardiovascular device demand.
Abbott's Electrophysiology sales climbed 13% as Volt PFA and TactiFlex Duo launches gained traction.
ABT completed enrollment in the CATALYST trial and reported positive Libre study results.
Abbott (ABT - Free Report) pursues a two-pronged investment strategy within its Medical Devices segment. The company is directing resources to support the momentum in Diabetes, Structural Heart, Electrophysiology and Heart Failure, which are high-growth areas. At the same time, it continues to invest to improve the growth outlook in foundational segments like Rhythm Management and Vascular. Despite greater investor attention on traditionally fast-growing categories, management notes that the foundational businesses are also generating very impressive returns.
In the first quarter of 2026, Medical Devices’ top line grew 8.5% year over year, led by strong performance in the cardiovascular device businesses. Going deeper, Electrophysiology sales increased 13%, aided by the launch of the Volt PFA catheter, which contributed to 14% growth in the United States. Another introduction, the TactiFlex Duo catheter, helped drive mid-teens growth in Europe. The business is poised to accelerate as both these launches continue to scale.
Abbott’s Rhythm Management sales grew 13%, making the third consecutive quarter of double-digit growth and continued market outperformance. In Heart Failure, 12% growth was driven by the Heart Assist Devices portfolio for the treatment of chronic and temporary conditions.
In Diabetes Care, continuous glucose monitoring (CGM) sales reached $2 billion. However, growth was impacted by an international tender renewal delay and a difficult year-over-year comparison. Management expects CGM sales to return to double-digit growth in the second quarter.
Abbott also reported several pipeline wins during the quarter. The company completed patient enrollment in its CATALYST trial, comparing the Amulet left atrial appendage device to oral anticoagulants in patients with Atrial fibrillation (AFib). The company also started the development work for an implantable extravascular ICD product and announced positive results from a randomized controlled trial, demonstrating that the Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management.
ABT’s Peer Updates
Medtronic (MDT - Free Report) recently received the CE mark for its Stealth AXiS surgical system, expanding access to advanced surgical technologies across Europe.The system is designed to support a wide range of clinical workflows and surgical environments and integrates planning, navigation and robotic execution into a single, modular platform. Medtronic completed the acquisition of CathWorks, the Israel-based leader in coronary digital health innovations.
Insulet (PODD - Free Report) has enrolled the first participant in a pivotal study for its fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D). The breakthrough innovation, FCL for T2D, is intended to further improve glycemic outcomes with less burden for users across diverse care settings. Insulet aims to remove barriers and expand access to AID, particularly in primary care, where roughly 70% of people with T2D are managed.
ABT Price Performance, Valuation & Estimates
Year to date, ABT shares have plunged 30.5% compared with the industry’s 23.2% decline.
Image Source: Zacks Investment Research
In terms of valuation, Abbott is trading at a forward 12-month Price/Earnings (P/E) of 15.31X, lower than its median and industry average.
Image Source: Zacks Investment Research
In the past 30 days, consensus estimates for Abbott’s earnings have trended downward.
View the Zacks #1 Rank List
Image: Bigstock
Abbott's Medical Device Strategy Supports Long-Term Growth Outlook
Key Takeaways
Abbott (ABT - Free Report) pursues a two-pronged investment strategy within its Medical Devices segment. The company is directing resources to support the momentum in Diabetes, Structural Heart, Electrophysiology and Heart Failure, which are high-growth areas. At the same time, it continues to invest to improve the growth outlook in foundational segments like Rhythm Management and Vascular. Despite greater investor attention on traditionally fast-growing categories, management notes that the foundational businesses are also generating very impressive returns.
In the first quarter of 2026, Medical Devices’ top line grew 8.5% year over year, led by strong performance in the cardiovascular device businesses. Going deeper, Electrophysiology sales increased 13%, aided by the launch of the Volt PFA catheter, which contributed to 14% growth in the United States. Another introduction, the TactiFlex Duo catheter, helped drive mid-teens growth in Europe. The business is poised to accelerate as both these launches continue to scale.
Abbott’s Rhythm Management sales grew 13%, making the third consecutive quarter of double-digit growth and continued market outperformance. In Heart Failure, 12% growth was driven by the Heart Assist Devices portfolio for the treatment of chronic and temporary conditions.
In Diabetes Care, continuous glucose monitoring (CGM) sales reached $2 billion. However, growth was impacted by an international tender renewal delay and a difficult year-over-year comparison. Management expects CGM sales to return to double-digit growth in the second quarter.
Abbott also reported several pipeline wins during the quarter. The company completed patient enrollment in its CATALYST trial, comparing the Amulet left atrial appendage device to oral anticoagulants in patients with Atrial fibrillation (AFib). The company also started the development work for an implantable extravascular ICD product and announced positive results from a randomized controlled trial, demonstrating that the Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management.
ABT’s Peer Updates
Medtronic (MDT - Free Report) recently received the CE mark for its Stealth AXiS surgical system, expanding access to advanced surgical technologies across Europe.The system is designed to support a wide range of clinical workflows and surgical environments and integrates planning, navigation and robotic execution into a single, modular platform. Medtronic completed the acquisition of CathWorks, the Israel-based leader in coronary digital health innovations.
Insulet (PODD - Free Report) has enrolled the first participant in a pivotal study for its fully closed-loop (FCL) automated insulin delivery (AID) system for type 2 diabetes (T2D). The breakthrough innovation, FCL for T2D, is intended to further improve glycemic outcomes with less burden for users across diverse care settings. Insulet aims to remove barriers and expand access to AID, particularly in primary care, where roughly 70% of people with T2D are managed.
ABT Price Performance, Valuation & Estimates
Year to date, ABT shares have plunged 30.5% compared with the industry’s 23.2% decline.
Image Source: Zacks Investment Research
In terms of valuation, Abbott is trading at a forward 12-month Price/Earnings (P/E) of 15.31X, lower than its median and industry average.
Image Source: Zacks Investment Research
In the past 30 days, consensus estimates for Abbott’s earnings have trended downward.
Image Source: Zacks Investment Research
Abbott currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.